Novavax
Nasdaq NVAX · Gaithersburg, MD
Works in Infectious disease · Respiratory
Novavax is a clinical trial sponsor based in Gaithersburg, MD, listed as Nasdaq NVAX. It has 1 active clinical trial with 6,500 planned participants, in Infectious disease and Respiratory. Since 2021 it has completed 26 trials and stopped 4 early.
Trial track record · since 2021
Financials · Nasdaq NVAX
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Novavax
Novavax is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 6,500 planned participants, in Infectious disease, Respiratory. Since 2021 it has completed 26 trials and stopped 4 early.
Novavax is based in Gaithersburg, MD and is listed as Nasdaq NVAX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Novavax; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-06-05.
Approve Suite is not affiliated with Novavax.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.